2. Search Result
Search Result
No matches for "

55251

" within the MedChemExpress (MCE) catalog. Here are the results you might be looking for.

7

Inhibitors & Agonists

1

Inhibitory Antibodies

2

Recombinant Proteins

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990033
    Anzurstobart

    CC-95251; BMS-986351

    		 CD47 Cancer
    Anzurstobart is a CD47/SIRPα inhibitor with human SIRPα Kd of 0.0541 nM and human SIRPα IC50 of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .
    Anzurstobart
  • HY-106019
    Liarozole

    R75251

    		 Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties .
    Liarozole
  • HY-106019C
    Liarozole dihydrochloride

    R75251 dihydrochloride

    		 Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties .
    Liarozole dihydrochloride
  • HY-106019A
    Liarozole hydrochloride

    R75251 hydrochloride

    		 Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole hydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole hydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole hydrochloride shows antitumoral properties .
    Liarozole hydrochloride
  • HY-106019B
    Liarozole fumarate

    R75251 fumarate

    		 Cytochrome P450 Metabolic Disease
    Liarozole fumarate, an imidazole derivative, is a potent inhibitor of cytochrome P450-dependent all-trans retinoic acid 4-hydroxylase and acts by increasing the levels of all-trans retinoic acid in plasma and skin.
    Liarozole fumarate
  • HY-106019CR
    Liarozole dihydrochloride (Standard)

    R75251 dihydrochloride (Standard)

    		 Reference Standards Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole (dihydrochloride) (Standard) is the analytical standard of Liarozole (dihydrochloride). This product is intended for research and analytical applications. Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties .
    Liarozole dihydrochloride (Standard)
  • HY-106019R
    Liarozole (Standard)

    R75251 (Standard)

    		 Reference Standards Cytochrome P450 RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    Liarozole (Standard) is the analytical standard of Liarozole. This product is intended for research and analytical applications. Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties .
    Liarozole (Standard)

Inquiry Online

Submit your filled information, we will contact you soon.

Salutation: * Country or Region:
* Applicant Name: * Organization Name:
* Department:    
* Email Address: * Product Name:
Cat. No.: * Requested quantity:
* Phone Number:    
Remarks:

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: